AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 308.4 USD | -0.55% |
|
+3.00% | +7.09% |
| 05-13 | Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating | MT |
| 05-09 | ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... |  |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
310.2
USD
Average target price
314.6
USD
Spread / Average Target
+1.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.09% | 166B | |
| +29.98% | 684B | |
| +30.34% | 568B | |
| -3.52% | 361B | |
| +18.59% | 329B | |
| +4.07% | 284B | |
| +16.21% | 240B | |
| +9.66% | 208B | |
| -6.83% | 200B | |
| -1.22% | 159B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia
